Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
Background: Several anticancer agents including paclitaxel have an inhibitory effect on angiogenesis. Aims: To compare the overall response rate and time to progression with changes in circulating angiogenic factors during palliative treatment with weekly paclitaxel. Material and methods: Patients with metastatic BC, ECOG 0-2, received weekly paclitaxel, concomitant with trastuzumab if HER2+ BC (n
